Limited Competition: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial not Allowed)

The National Institutes of Health, through the National Institute of Neurological Disorders and Stroke and the National Institute on Aging, is issuing a single-source U19 cooperative agreement under RFA-NS-27-011. This funding opportunity is specifically designated for Massachusetts General Hospital to support the renewal of the Post-Stroke Vascular Cognitive Impairment and Dementia (VCID) program. The initiative focuses on researching specific subsets of stroke events that lead to cognitive impairment and dementia in the United States, utilizing a multi-site clinical research approach. While the program emphasizes collaborative expertise in genetics, neuroimaging, and biostatistics, clinical trials are explicitly not allowed. The project has a maximum performance period of four years, with direct costs not to exceed 26.7 million dollars, although the agency intends to commit up to 10 million dollars in the 2027 fiscal year. Award decisions are based on scientific and technical merit, fund availability, and program relevance, with a primary focus on the overall impact and the feasibility of the proposed approach. Key requirements include maintaining active registrations in SAM and eRA Commons, adhering to strict cybersecurity incident reporting within 48 hours of discovery, and submitting manuscripts to the NINDS Program Officer within two weeks of acceptance. The application structure is a multi-component submission requiring an overall project description and specific cores for administration, statistics, recruitment, and repository management.